NORTH BRUNSWICK, N.J. -- Advaxis,
Incorporated (OTCBB: ADXS), has engaged the Numoda Corporation, a leading clinical trial and logistics management company,
to oversee Phase II clinical activity with ADXS11-001 for the treatment
of invasive cervix cancer and cervical intraepithelial neoplasia (CIN;
cervical dysplasia).
Numoda will integrate oversight and logistical functions with the clinical research organizations (CRO), contract laboratories, academic laboratories and statistical groups involved.
“The Numoda Corporation offers experience and resources that will enable Advaxis to execute multiple high quality clinical trials with precision, efficiency, high quality data and a rapid final study report,” commented Advaxis EVP of Science and Operations Dr. John Rothman.
Advaxis anticipates that the Numoda Corporation’s involvement will help expedite the clinical trial process. The Company anticipates initiating trial activity in September 2009 as described and delineated in the Company’s most recent 10-Q filing. For more information on public filing documents, please visit the US Security and Exchange Commission’s website at: www.sec.gov.
About the Numoda Corporation
The Numoda Corporation is a leading provider of clinical trial information and logistics services to promising life sciences companies. Numoda's services strengthen the business case for new therapies by ensuring efficient deployment of funds and immediate reporting for early assessment of progress to improve conditions for the acquisition of funding, licensing and partnering money for future success. The business offerings include business evaluation, budget projections and oversight; in conjunction with comprehensive management of clinical trials, patented information systems, logistics management and reporting tools with early transparency.
Advaxis, Incorporated
Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes (Lm) cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board. Advaxis is developing attenuated live Lm vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer.
For further information on the Company, please visit: www.advaxis.com.
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Numoda will integrate oversight and logistical functions with the clinical research organizations (CRO), contract laboratories, academic laboratories and statistical groups involved.
“The Numoda Corporation offers experience and resources that will enable Advaxis to execute multiple high quality clinical trials with precision, efficiency, high quality data and a rapid final study report,” commented Advaxis EVP of Science and Operations Dr. John Rothman.
Advaxis anticipates that the Numoda Corporation’s involvement will help expedite the clinical trial process. The Company anticipates initiating trial activity in September 2009 as described and delineated in the Company’s most recent 10-Q filing. For more information on public filing documents, please visit the US Security and Exchange Commission’s website at: www.sec.gov.
About the Numoda Corporation
The Numoda Corporation is a leading provider of clinical trial information and logistics services to promising life sciences companies. Numoda's services strengthen the business case for new therapies by ensuring efficient deployment of funds and immediate reporting for early assessment of progress to improve conditions for the acquisition of funding, licensing and partnering money for future success. The business offerings include business evaluation, budget projections and oversight; in conjunction with comprehensive management of clinical trials, patented information systems, logistics management and reporting tools with early transparency.
Advaxis, Incorporated
Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes (Lm) cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board. Advaxis is developing attenuated live Lm vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer.
For further information on the Company, please visit: www.advaxis.com.
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
No comments:
Post a Comment